Suppr超能文献

美国中性粒细胞减少性癌症患者的死亡率:与医院容量的关系。

Mortality Among Neutropenic Cancer Patients Within the United States: The Association With Hospital Volume.

机构信息

Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel.

Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel.

出版信息

JCO Oncol Pract. 2021 Apr;17(4):e582-e592. doi: 10.1200/OP.20.00115. Epub 2021 Jan 13.

Abstract

PURPOSE

Neutropenia is a serious complication of chemotherapy in patients with solid tumors. The influence of hospital volume on outcomes in patients with neutropenia has been little investigated. We hypothesized that large-volume hospitals would have reduced mortality rates for neutropenic patients compared with small-volume institutions.

METHODS

We used the Nationwide Inpatient Sample database of the Healthcare Cost and Utilization Project, for the years 2007-2011. All adult inpatient episodes with a diagnosis of both neutropenia and solid-tumor malignancy were included. Hospital volume was defined as the number of neutropenic cancer episodes per institution per year. Mortality was defined as death during admission. A multilevel mixed-effects logistic regression model was applied.

RESULTS

Twenty thousand three hundred and ten hospitalizations were included in the study, from 1,869 different institutions. Median age was 62 years. The overall inpatient mortality was 2.3%, and was dependent on age (age 50-59 years-1.6% and age 80-89 years-5.3%). The median number of neutropenic inpatient episodes in each institution per year was 14 (range, 1-168). Mortality was 3.3%, 2.7%, 2.2%, 2.2%, and 1.2% for each quintile of hospital volume (from lowest to highest volume, < .001). Likewise, the proportion discharged home was 85.7%, 90.3%, 91.5%, 92.7%, and 95.4% ( < .001). The association between hospital volume and mortality remained significant after adjustment for patient-level and hospital-level variables.

DISCUSSION

Patients with neutropenia hospitalized in large-volume institutions have a substantially lower mortality compared with those hospitalized at low-volume institutions. Further study is required to validate our findings or overcome potential biases, understand mechanism, and investigate how smaller institutions can improve outcomes.

摘要

目的

中性粒细胞减少是实体瘤患者化疗的严重并发症。医院容量对中性粒细胞减少患者结局的影响尚未得到充分研究。我们假设大容量医院的中性粒细胞减少患者死亡率会低于小容量机构。

方法

我们使用了医疗保健成本和利用项目的全国住院患者样本数据库,时间范围为 2007 年至 2011 年。所有伴有中性粒细胞减少和实体瘤恶性肿瘤诊断的成年住院患者均包括在内。医院容量定义为每年每个机构的中性粒细胞减少癌症例数。死亡率定义为住院期间死亡。采用多级混合效应逻辑回归模型。

结果

研究共纳入了 2310 例住院患者,来自 1869 家不同的医院。中位年龄为 62 岁。总体住院死亡率为 2.3%,且与年龄相关(50-59 岁年龄组为 1.6%,80-89 岁年龄组为 5.3%)。每家医院每年中性粒细胞减少住院例数的中位数为 14 例(范围为 1-168 例)。死亡率分别为每个医院容量五分位数的 3.3%、2.7%、2.2%、2.2%和 1.2%(从最低到最高容量,<0.001)。同样,出院回家的比例分别为 85.7%、90.3%、91.5%、92.7%和 95.4%(<0.001)。在调整患者水平和医院水平变量后,医院容量与死亡率之间的关联仍然显著。

讨论

在大容量医院住院的中性粒细胞减少患者的死亡率明显低于在低容量医院住院的患者。需要进一步研究来验证我们的发现或克服潜在的偏差,了解机制,并研究较小的机构如何提高治疗效果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验